Drugs / ABBV-1088
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06579300 | Sep 2024 → Sep 2025 | — | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06414798 | May 2024 → Feb 2025 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-1088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06579300 ↗ |
| Route | Oral | “Oral Capsule” NCT06414798 ↗ |